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Abstract 
Objective: The relationship between insomnia symptoms and cognitive performance 
is unclear, particularly at the population level. We conducted the largest examination 
of this association to date through analysis of the UK Biobank, a large population-
based sample of adults aged 40-69 yrs. We also sought to determine associations 
between cognitive performance and self-reported chronotype, sleep medication use, 
and sleep duration. 
Methods: This cross-sectional, population-based study involved 477,529 participants, 
comprising 133,314 with frequent insomnia symptoms (age: 57.4 ± 7.7 yrs; 62.1% 
female) and 344,215 controls without (age: 56.1 ± 8.2 yrs; 52.0% female). Cognitive 
performance was assessed through a touchscreen test battery probing reasoning, 
basic reaction time, numeric memory, visual memory and prospective memory. 
Adjusted models included relevant demographic, clinical and sleep variables.  
Results: Frequent insomnia symptoms were associated with cognitive impairment in 
unadjusted models, however these effects were reversed after full adjustment, 
leaving those with frequent insomnia symptoms showing statistically better cognitive 
performance over those without. Relative to intermediate chronotype, evening 
chronotype was associated with superior task performance, while morning 
chronotype was associated with the poorest performance. Sleep medication use and 
both long (>9hrs) and short (<7hrs) sleep duration were associated with impaired 
performance. 
Conclusions: Our results suggest that after adjustment for potential confounding 
variables, frequent insomnia symptoms may be associated with a small statistical 
advantage, which is unlikely to be clinically meaningful, on simple neurocognitive 
tasks. Further work is required to examine mechanistic underpinnings of an apparent 
evening chronotype advantage in cognitive performance, as well as impairment 
associated with morning chronotype, sleep medication use, and sleep duration 
extremes. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
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Highlights 
• how different aspects of sleep health relate to cognition is unclear 
• we examined sleep and cognitive performance in ~500,000 adults aged 40-69 
years  
• unexpectedly, frequent insomnia symptoms were independently associated 
with better cognitive performance (effect size differences were very small) 
• sleep medication, and long/short sleep duration were linked to cognitive 
impairment 
• morningness was linked to impairment, while eveningness showed superior 
performance 
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Introduction  
 
Insomnia disorder is defined as persistent difficulties with sleep initiation and/or 
maintenance, resulting in significant impairment to daytime functioning. At the 
symptom level, insomnia affects up to one-third of the adult population, while 
persistent insomnia disorder affects approximately 10-12% and is associated with 
increased risk for cardiovascular disease, depression and early mortality.1,2 Both 
daytime functioning and quality of life are known to be severely affected in those with 
insomnia and often drive treatment-seeking.3-5 More specifically, previous work 
shows that the most commonly cited areas of daytime dysfunction are problems with 
fatigue, work performance, cognitive performance and emotion regulation6. Insomnia 
has also been associated with a range of serious and non-serious sleep-related 
accidents7. 
 
While experimental sleep loss engenders reliable cognitive impairment, particularly 
for vigilance, complex attention and working memory,8 there has been comparatively 
little work on insomnia. In general, the field has been characterised by mixed 
findings, with some studies showing impairment and others failing to observe 
differences from controls.9 Nevertheless, meta-analytic data suggest that patients 
exhibit reliable impairments in tasks probing episodic memory, working memory and 
problem solving, with small-to-medium effect sizes.10 Recent, well-controlled studies 
find evidence of insomnia-related impairments in switching of attention and working 
memory,11 and sustained attention and episodic memory.12 However, there continues 
to be conflicting findings in the insomnia literature13-15 and studies generally recruit 
small samples of patients with “primary insomnia”, who are otherwise healthy.  
 
Larger epidemiology-based studies of insomnia symptoms and cognitive 
performance similarly display mixed results: showing evidence of impairment,16 no 
evidence of impairment,17 or impairment only for specific insomnia sub-groups.15,18 
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To our knowledge, no study has investigated insomnia symptoms and cognitive 
performance in a large population-based sample of middle-aged adults, with a 
standardised test battery, while simultaneously appraising the influence of other 
important sleep variables, including chronotype, sleep duration, and sleep 
medication. 
 
The aim of the present study was to conduct the largest investigation of insomnia 
symptoms and cognitive performance to date, through analysis of UK biobank data. 
The UK biobank is a large population-based study of >500,000 adults aged between 
40 and 69, providing a unique opportunity to assess associations in groups of poor 
and good sleepers, and to adequately control for the influence of several potential 
confounding variables. We hypothesised that insomnia would be independently 
associated with impairments in all measures of cognition (reasoning, basic reaction 
time, numeric memory, visual memory and prospective memory) after controlling for 
potential confounding variables. As a secondary aim we examined associations 
between cognitive performance and chronotype, sleep medication use, and self-
reported sleep duration. 
 
Methods 
Participants 
Details of the UK Biobank are available elsewhere.19 In brief, adults aged 40 to 69 
years who were registered with the UK National Health Service and living within 25 
miles of a study assessment centre were invited to participate. Approximately 9 
million invitations led to a final sample of 501,718 participants. For the purposes of 
the present study, participants were excluded if they self-reported a neurological 
condition (e.g., neurodegenerative disease, stroke, head injury, epilepsy; n=22,065), 
had a diagnosis of sleep-disordered breathing (n=1,511), or had incomplete data for 
insomnia symptoms (n=613), leaving a total of 477,529. Twenty-eight percent of the 
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sample reported frequent insomnia symptoms (n=133,314; mean age = 57.4 yrs, SD 
= 7.7 yrs; 62.1% female), while the remaining 72% of participants made up the 
comparison group (n=344,215; mean age = 56.1 yrs, SD = 8.2 yrs; 52.0% female). 
This comparison group was comprised of those reporting insomnia symptoms 
“sometimes” [48%] and “never/rarely” [28%]. 
 
Procedure and measurements 
All UK Biobank research procedures were approved by the NHS National Research 
Ethics Service (Ref. 11/NW/0382). All participants gave written informed consent. 
Assessments took place at 22 centres across England, Scotland and Wales between 
2006 and 2010. Questionnaires and cognitive assessments were administered in a 
standardised order via a computerized touchscreen interface, followed by a face-to-
face interview with a research nurse to obtain additional data. Assessments of sleep-
related variables and cognitive performance took place in a single visit lasting 
approximately 90 minutes. 
 
Sleep-related variables 
To assess insomnia symptoms, participants were asked “Do you have trouble falling 
asleep at night or do you wake up in the middle of the night?" with responses 
“never/rarely”, “sometimes”, and “usually”. Participants were categorised as having 
frequent insomnia symptoms if they answered “usually” to this question, while the 
remaining participants made up the control group without frequent insomnia 
symptoms. Chronotype was assessed using the following question, “Do you consider 
yourself to be”…: “definitely a ‘morning’ person”, “more a ‘morning’ than ‘evening’ 
person”, “more an ‘evening’ than ‘morning’ person”, “definitely an ‘evening’ person”. 
For the purposes of the present study, we collapsed the two middle responses into 
an “intermediate” chronotype category, permitting comparisons with the ‘definitely 
morning’ and ‘definitely evening’ groups. Sleep duration was recorded as number of 
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reported hours to the following question “About how many hours sleep do you get in 
every 24 hours? (please include naps)”. Given previously established U-shape 
relationships with health and cognition,20 we categorised sleep duration into short (<7 
hrs), normal (7-9 hrs) and long (>9hrs) based on recent guidelines.21 Finally, as a 
manipulation check to support group categorisation (insomnia symptoms vs. no 
insomnia symptoms), subjective daytime impairment was coded based on answers 
to the following question: “Over the past two weeks, how often have you felt tired or 
had little energy?”, with the following response options: “not at all”, “several days”, 
“more than half the days”, or “nearly every day”. 
 
Cognitive Performance 
Five cognitive measures were administered via computerised touchscreen 
interface.22 Time to complete all five cognitive tests was approximately 15 minutes. 
The tests were designed specifically for UK Biobank, in order to allow administration 
at scale without examiner supervision. The tasks show evidence of an underlying 
performance factor and good stability over time, with the exception of verbal memory 
performance which has a comparatively lower intraclass correlation coefficient.22 
 
Briefly, the assessments included: 
• reasoning: this task assessed the ability to solve thirteen verbal and numeric 
reasoning problems. Each problem had five possible response options. The 
dependent variable was total number of correct answers given (range 0-13) 
within a two-minute period, with higher scores indicating better performance; 
• basic reaction time: this task was delivered in the style of the card game, 
‘snap’, and requested participants to respond with a button press when they 
detected the appearance of a matching pair of symbols. The dependent 
variable was mean response time in milliseconds across 12 matching-pair 
trials. RT values were log-transformed due to skewed distribution (ln x); 
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• numeric short-term memory: In this task a string of numbers were presented 
on the screen which subsequently disappeared. Participants were asked to 
then enter the number string from memory, in reverse order, via keypad 
response. The dependent variable was maximum string length recalled 
correctly (range: 0-12), with higher scores indexing better performance. The 
test was discontinued after five successive incorrect responses at string 
length = 2; 
• visual memory: In this task six card-pairs of symbols were presented on-
screen in a random pattern. Cards were then turned face down on the screen 
and participants were asked to locate as many symbol pairs as possible in as 
few attempts as possible. The dependent variable was the number of errors 
made during pairs matching (range 0-146), which was log-transformed due to 
skewed distribution and zero-inflation (ln (x+1)); 
• prospective memory: In this task participants were asked to remember to 
carry out a pre-planned instruction after a filled interval. At the beginning of 
the test battery they were presented with the following instruction: “At the end 
of the games we will show you four coloured symbols and ask you to touch 
the blue square. However, to test your memory, we want you to actually touch 
the orange circle instead.” If participants remembered to touch the orange 
circle on first attempt they were coded as “correct” (1), while those failing to 
do so were set to 0. 
 
Demographic data 
Demographic data included age, sex and neighborhood-level socioeconomic status 
as measured by the Townsend index of material deprivation. For statistical analyses, 
socioeconomic status was log-transformed due to skewed distribution using an ‘ln 
(x+7)’ equation (minimum of non-transformed index: -6.26). Educational qualifications 
were recorded, and were dichotomised according to whether or not participants held 
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a college / university degree. We also included body mass index (BMI) as a covariate 
in adjusted analyses. 
 
Medication and clinical data 
Current medications were self-reported to the research nurse, and participants were 
dichotomised according to whether or not they were taking sleep medication 
(sedatives and hypnotics), any other psychotropic medication (mood stabilisers, 
antidepressants, antipsychotics), or antihypertensive medication (ACE inhibitors, 
angiotensin II antagonists, beta blockers, calcium channel blockers, diuretics). 
Current depressive symptoms were assessed using the following question, “Over the 
past two weeks, how often have you felt down, depressed or hopeless?” with the 
following response options: “not at all”, “several days”, “more than half the days” or 
“nearly every day”. For the purpose of the present analyses, those scoring “several 
days”, “more than half the days”, or “nearly every day” were coded in the “depressive 
symptoms” category, while those scoring ”not at all” were considered in the “no 
depressive symptoms” category. In addition, participants were dichotomised 
according to whether or not they reported hypertension or any cardiovascular 
disease. 
 
Analyses 
 
Descriptive data presentation included mean values and standard deviations, as well 
as the proportion of the sample reporting specific questionnaire response options. 
Questionnaire response options, ‘do not know’ or ‘prefer not to answer’, were 
handled as missing values. For cognitive dependent variables, sample size varied 
across tests because the reasoning and prospective memory tests were added after 
commencement of data collection, while the numeric memory task was included from 
the outset but subsequently removed due to time constraints.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
In a first step (unadjusted analyses, model 1), the association between insomnia 
status (frequent insomnia symptoms vs. those without frequent insomnia symptoms) 
and cognitive performance was analysed using four linear models, with insomnia 
status as the single predictor variable and reasoning, basic reaction time, numeric 
memory and visual memory as dependent variables. Association between insomnia 
status and prospective memory performance was investigated using a logistic model. 
In a second step (model 2), age, sex, socioeconomic status and education were 
added as covariates in the linear and logistic models described in model 1. In a third 
step (model 3), chronotype (with the intermediate type as the reference category), 
sleep medication use, BMI as a continuous variable, hypertension, antihypertensive 
medication, cardiovascular disease, depressive symptoms, and psychotropic 
medication were added as further covariates. In a final step (model 4), sleep duration 
(with 7-9 hrs as the reference category) was inserted as an additional predictor of 
cognitive performance. We therefore report unadjusted and multivariate-adjusted 
relationships between insomnia status and cognitive outcomes. For chronotype, 
sleep duration and sleep medication we report only the fully adjusted relationships 
(model 4) controlling for all demographic, clinical and remaining sleep variables. 
Given that we analysed five cognitive tests, the alpha level was set at p<0.01 for all 
analyses. 
 
Results 
Sample description 
Sociodemographic data for the sample are presented in Table 1. Those with frequent 
insomnia symptoms were older and more likely to be female, reported shorter sleep 
duration, were more likely to report using sleep medication, were less likely to hold a 
university or college degree, were from a lower socioeconomic background, had a 
higher BMI, were more likely to report hypertension, use of antihypertensive 
medication or cardiovascular disease, were more likely to report recent depressive 
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symptoms and were more likely to report taking psychotropic medication (all 
p<0.001).  
 
[Insert Table 1 here] 
 
Association between insomnia symptoms and cognitive performance 
Results from statistical models are presented in Table 2. In unadjusted analyses 
(model 1), frequent insomnia symptoms were associated with worse performance on 
the reasoning test, basic reaction time test, numeric memory test, and visual memory 
test. There was no statistically significant association between insomnia status and 
performance on the prospective memory test after correction for multiple testing. 
 
[Insert Table 2 here] 
 
In age, sex, socioeconomic status and education-adjusted analyses (model 2), 
insomnia was no longer associated with performance on the reasoning test or 
numeric memory test. Adjustment revealed that insomnia was associated with 
statistically better performance on the basic reaction time test, visual memory test 
and prospective memory test. 
 
Further adjustment for clinical and sleep-related variables (models 3 and 4) showed 
that frequent insomnia symptoms were associated with better performance on the 
reasoning test, basic reaction time test, visual memory test, and prospective memory 
test, compared to those without frequent insomnia symptoms. There was no 
statistically significant independent association between insomnia status and 
performance on the numeric memory test. 
 
Chronotype, sleep medication, and sleep duration 
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27.0% of the sample were categorized as morning chronotype, 64.0% as 
intermediate, and 8.9% as evening chronotype. In fully adjusted analyses (model 4; 
see Table 3), evening chronotype was associated with superior task performance on 
the reasoning test, basic reaction time test, visual memory test, and prospective 
memory test, relative to those with an intermediate chronotype, while there was no 
significant association with task performance on the numeric memory test. On the 
contrary, morning chronotype, relative to intermediate chronotype, was associated 
with poorer performance on the reasoning test, basic reaction time test, numeric 
memory test, visual memory test, and prospective memory test. 
 
[Insert Table 3] 
 
Sleep medication use was associated with reduced performance on the reasoning 
test, basic reaction time test, and prospective memory test, but not on the numeric 
memory test or visual memory test. 
 
73.7% of the sample reported sleep duration between 7 and 9 hours, 24.6% reported 
sleep duration <7 hours, while 1.7% reported sleep duration >9 hours. Both short (<7 
hrs) and long (>9 hrs) sleep duration were associated with poorer performance on 
the reasoning test, basic reaction time test, numeric memory test, visual memory 
test, and prospective memory test.  
 
Discussion 
The principal aim of the present study was to examine cross-sectional associations 
between insomnia symptoms and cognitive performance in a large population-based 
sample. We also sought to assess relationships between cognitive performance and 
sleep duration, chronotype and sleep medication use. Prevalence, demographic and 
comorbidity profile of those with insomnia symptoms was consistent with previous 
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epidemiological investigations.1 Unadjusted analyses revealed that those with 
frequent insomnia symptoms displayed impairment across all cognitive tasks (except 
prospective memory); however, intermediate adjustment for demographic variables 
rendered these associations non-significant or reversed their direction. Full 
adjustment (model 4) for demographic, medical and sleep-related variables left those 
with frequent insomnia symptoms with a small, but statistically significant advantage 
over those without insomnia for all cognitive measures (except numeric memory). On 
the other hand, sleep medication use, as well as both long (>9 hrs) and short (<7hrs) 
sleep duration were independently associated with cognitive impairment, while 
evening chronotype was linked to better task performance. 
 
Our study represents the largest investigation of insomnia symptoms and cognitive 
performance to date and is consistent with results from population-based studies 
which similarly failed to observe negative relationships,15,17 whilst conflicting with 
others.16,24 Clearly our study stands apart with respect to sample size and ability to 
control for the influence of multiple confounding sleep and non-sleep variables. The 
apparent small, but statistical advantage of those with insomnia versus those without 
was unexpected and is unlikely to be clinically meaningful [note, effect size 
differences in SD units = .044 (reasoning), .035 (reaction time) and .022 (visual 
memory)]. Nevertheless, it is worth reflecting on what factors may contribute to these 
consistent effects. Typical of large epidemiological-based studies, there remains the 
possibility of unmeasured confounding that may explain group differences. We note 
that a recent report on UK Biobank data similarly found, unexpectedly, that those 
with a history of probable single episode depression or probable recurrent 
depression displayed a small but statistically significant cognitive advantage over 
controls.23 It is possible that our samples are overlapping.  
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There may also be trait factors relevant to poor sleepers that aid compensation 
and/or performance facilitation. For example, hyperarousal across cognitive, 
emotional and neurophysiological levels is characteristic of insomnia25 and has been 
suggested to support cognitive performance on relatively brief tasks with low 
cognitive load.26 In support of this, at least two studies have observed quicker 
reaction times on basic vigilance tasks in insomnia patients relative to controls.27,28 
Hyperarousal has in turn been proposed to hinder performance on more cognitively 
challenging tasks29,30 and it may be that tests used in the present study were not of 
sufficient sensitivity and/or complexity to unmask insomnia-related impairment.31   
 
Another possibility is that unmeasured personality traits known to be associated with 
insomnia may contribute to enhanced cognitive performance. We and others have 
shown that those with insomnia often display high levels of perfectionism, captured 
through questionnaire and behavioural measures.32-36 Preliminary work suggests that 
high levels of perfectionism may confer advantage on specific task-dependent 
variables under certain conditions.37 However, studies have also revealed that 
perfectionistic traits (and associated processes, like rumination) may be obstructive 
to task performance.38 Thus, the drivers behind the observed statistical advantage 
remain speculative and unclear, but could involve both etiological and 
methodological factors. Of note, supplementary analysis (see supplementary Table 
1) comparing those reporting insomnia symptoms “sometimes” with those reporting 
insomnia symptoms “never/rarely” did not reveal group differences in adjusted 
models. However, consistent with results presented above, those with frequent 
insomnia symptoms performed better relative to those reporting insomnia symptoms 
“never/rarely”. There is, therefore, no clear dose-response effect between frequency 
of insomnia symptoms and cognitive performance. 
 
Chronotype, sleep medication, and sleep duration 
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While sleep disturbance was not independently associated with task impairment we 
observed associations between cognitive performance and chronotype, sleep 
medication use and sleep duration. Evening chronotype was associated with better 
performance across all tasks (except numeric memory), while those endorsing a 
morning preference performed worse than the intermediate group. It must be noted 
that effect size differences for evening and morning chronotypes, relative to the 
intermediate group, were in the very small range (SD units difference: .023-.116). 
This is the first time that such relationships have been observed in a large 
population-based sample with a standardized test battery, supporting a range of 
smaller studies reporting on academic achievement, salary and intelligence 
outcomes.39-42 We note, however, that our findings are at odds with evidence from 
diffusion tensor imaging showing white matter deficits in frontal and temporal lobes, 
cingulate gyrus and corpus callosum in evening types.43 Although we were unable to 
investigate time of testing in relation to chronotype and performance, assessments 
took place during standard office hours and therefore would be expected to work 
against evening types, rather than account for superior performance. Findings are 
consistent with our recent biobank-GWAS which found that genetic loci underlying 
eveningness were associated with higher educational attainment.44 Importantly, we 
find chronotype-performance associations independent of educational background 
and socioeconomic status. Theoretical conceptualisations of an evening chronotype 
advantage and morning type impairment remain under-developed45 but our work 
suggests these are likely to be reliable associations at the population level.   
 
We observed that sleep medication and long/short sleep duration are independently 
associated with poorer cognitive performance (SD units difference: .048-.132 [sleep 
medication]; .013-.069 [short sleep duration]; .094-.269 [long sleep duration]). These 
effects have been shown across a range of study designs and samples17,20,46,47 but 
our study is particularly noteworthy given our ability to partial out the effect of 
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potential confounders, including both sleep and non-sleep variables. We were not 
able to record history or duration of sleep medication use but both acute and chronic 
use of benzodiazepines/benzodiazepine receptor agonists is known to be associated 
with cognitive and psychomotor impairment,47 while their discontinuation in chronic 
users is associated with improved cognitive status.48 Sleep medication use appears 
to be more robustly associated with cognitive impairment than insomnia symptoms, 
which may have important clinical implications. It of course remains possible that 
extremes of sleep duration and sleep medication act as proxies for underlying poor 
health, accounting for associated impairment. Future, longitudinal efforts are needed 
to examine this possibility more directly, incorporating a greater number of potential 
health-related confounds. Finally, examination of associations between sleep traits 
and functional and structural neuroimaging parameters is now required to shed light 
on putative brain mechanisms underlying performance profiles. 
 
Limitations 
Our study has several important caveats. First, this was a cross-sectional study and 
therefore our findings cannot elucidate causality. Second, our cognitive dependent 
variables were created for brief completion on large numbers of participants and 
hence have not undergone formal validation. In partial mitigation, principal 
components analyses support an expected underlying performance (g) factor across 
tasks, and test-retest suggests good stability for most task dependent variables.22 
Moreover, associations with variables in the expected direction (e.g. with age, 
education), evidence of impairment in those with psychiatric disorder,23 and 
associations with several genetic variants49 provide further support of task validity. 
However, tasks were brief and did not parametrically manipulate cognitive load, and 
the battery did not sample additional domains of cognition; potentially contributing to 
limited sensitivity for insomnia-related impairment. Third, our sleep trait predictor 
variables were limited by their low-resolution, reflecting just single item self-report 
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questions. For example, our sleep duration estimate included daytime naps and 
therefore we could not tease apart the contribution of night and day-time sleep, which 
may have influenced group categorization and, by extension, associations with our 
dependent variables of interest. We could not investigate subtypes of insomnia that 
may have unique relationships with cognitive impairment.16 Specifically, we were not 
able to categorise participants into insomnia disorder since we lacked information on 
chronicity of sleep problems, quantitative criteria (e.g. minutes for sleep-onset 
latency, wake-time during the night), attribution for daytime cognitive impairment, or 
help-seeking. Greater precision around these factors and objective sleep data may 
have identified sub-groups of participants with cognitive impairment.12,15,18,30,50 Our 
results therefore can only speak to frequent insomnia symptoms at the population 
level. Fourth, our sample age was restricted to those predominantly in middle-age. It 
may be that insomnia confers greatest risk to cognitive impairment in elderly 
samples.24 Fifth, while the UK biobank represents a large and unique resource, 
method of recruitment and low response rate (5.5%) may have resulted in selection 
biases, potentially limiting generalizability to the broader UK population.51 Sixth, 
sample size differed across statistical models owing to missing data for specific 
covariates of interest. However, we note that when analyses are restricted to 
complete data across all models, findings remain unchanged (see Supplementary 
Table 2). Finally, our analyses are based exclusively on Gaussian linear models, and 
we have not tested whether nonlinear and/or non-Gaussian models would reveal 
more nuanced associations between our predictor and outcome variables.  
 
Conclusion 
In our large UK sample frequent insomnia symptoms were not independently 
associated with cognitive impairment. Indeed, contrary to our hypotheses, we found 
a small statistical advantage for those with frequent insomnia symptoms over those 
without, which is unlikely to be clinically meaningful. Our data in no way undermine 
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subjective daytime reports of those with poor sleep, since task performance may not 
fully map onto daytime phenomenology.4,10 We cannot exclude the possibility that 
those with insomnia disorder or discrete sub-groups of insomnia do not exhibit 
reliable performance impairment. Reliability of, and mechanisms underpinning, the 
small evening chronotype advantage and morning chronotype disadvantage require 
further examination, including consideration of time of testing. Finally, our results 
corroborate cognitive risk associated with sleep medication use as well as both long 
and short sleep duration. 
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Table 1: Sociodemographic and clinical data for study sample. Groups differed 
significantly for all variables (p<.001).  
 
 Subgroup with 
frequent 
insomnia symptoms 
Subgroup without 
frequent 
Insomnia symptoms 
N 133,314 344,215 
Age (yrs) 57.4 ± 7.7 56.1 ± 8.2 
Sex (% female) 62.1 % 52.0 % 
Sleep duration (hrs) 6.7 ± 1.3  7.3 ± 1.0 
Sleep medication (%) 2.1 % 0.4 % 
Education (% with university/ 
college degree) 
35.9 % 41.1 % 
Socioeconomic status* -1.16 ± 3.16 -1.39 ± 3.04 
BMI (kg/m²) 27.8 ± 5.1 27.2 ± 4.6 
Hypertension (%) 29.9 % 23.8 % 
Antihypertensive medication (%) 25.4 % 19.8 % 
Cardiovascular disease (%) 11.0 % 7.9 % 
Depressive symptoms (%) 34.5 % 19.1 % 
Psychotropic medication (%) 11.0 % 5.8 % 
 
BMI: body mass index; *Townsend Index of Material Deprivation. 
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  Table 2: Unadjusted and multivariate-adjusted relationships between insomnia status and cognitive 
performance. β values indicate unadjusted (model 1) and adjusted (models 2, 3 and 4) group differences 
between those with frequent insomnia symptoms and those without frequent insomnia symptoms. 
 
 
Cognitive Domain  Model 1# Model 2## Model 3### Model 4#### 
     
Reasoning β = -1.2 x 10-1 *** β = 1.9 x 10-2 β = 5.9 x 10-2 ***  β = 9.5 x 10-2 *** 
  (n = 158,180) (n = 134,295) (n = 115,935) (n = 115,668) 
Reaction Time β = 1.4 x 10-2 *** β = -2.2 x 10-3 ** β = -5.9 x 10-3 *** β = -6.7 x 10-3 *** 
 (n = 473,144) (n = 386,588) (n = 333,095) (n = 332,303) 
Numeric memory β = -1.0 x 10-1 *** β = -1.8 x 10-2 β = 4.9 x 10-3 β = 1.6 x 10-2 
  (n = 48,091) (n = 40,151) (n = 34,844) (n = 34,753) 
Visual Memory β = 1.4 x 10-2 *** β = -9.0 x 10-3 ** β = -1.3 x 10-2 *** β = -1.4 x 10-2 *** 
 (n = 473,955) (n = 372,318) (n = 334,779) (n = 333,966) 
Prospective Memory β = -2.7 x 10-2 β = 6.1 x 10-2 *** β = 1.1 x 10-1 *** β = 1.5 x 10-1 *** 
 (n = 163,077) (n = 136,770) (n = 117,721) (n = 117,438) 
 
#unadjusted analyses; ##adjusting for age, sex, socioeconomic status and education; ###adjusting for age, sex, 
socioeconomic status, education, BMI, hypertension, cardiovascular disease, antihypertensive medication, 
depressive symptoms, psychotropic medication, sleep medication, chronotype; ####adjusting for Model 3 
variables plus sleep duration. * p < 0.01; ** p < 0.001; *** p < 0.0001
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Table 3: Multivariate-adjusted relationships between sleep-related variables (chronotype, sleep 
medication, sleep duration) and cognitive performance (Model 4).  
 
  
 Reasoning 
(n = 115,668) 
 
Reaction time  
(n = 332,303) 
Numeric 
memory 
(n = 34,753) 
 
Visual memory 
(n = 333,966) 
Prospective 
memory 
(n = 117,438) 
Morning 
chronotype# 
 
β = -2.5 x 10-1 
p < 10-72 
β = 5.4 x 10-3 
p < 10-13 
β = -1.1 x 10-1 
p < 10-10 
 
β = 2.6 x 10-2  
p < 10-22 
β = -3.6 x 10-1 
p < 10-102 
Evening 
chronotype# 
β = 1.4 x 10-1 
p < 10-10 
β = -5.0 x 10-3 
p < 10-5 
β = 4.8 x 10-2 
p = 0.049 
 
β = -1.5 x 10-2 
p < 10-4 
β = 1.1 x 10-1 
p < 10-3 
Sleep 
medication 
(vs. none) 
β = -2.9 x 10-1 
p < 10-4 
 
β = 2.0 x 10-2 
p < 10-7 
β = -1.3 x 10-1 
p = 0.114 
β = 3.2 x 10-2 
p = 0.016 
β = -2.5 x 10-1 
p = 0.002 
Sleep duration  
< 7 h$ 
β = -1.5 x 10-1 
p < 10-24 
 
β = 3.6 x 10-3 
p < 10-5 
β = -4.4 x 10-2 
p = 0.009 
β = 8.3 x 10-3 
p = 0.002 
β = -1.8 x 10-1 
p < 10-22 
 Sleep duration  
> 9 h$ 
β = -6.4 x 10-1 
p < 10-34 
 
β = 2.7 x 10-2 
p < 10-24 
β = -3.1 x 10-1 
p < 10-6 
β = 6.2 x 10-2 
p < 10-9 
β = -3.9 x 10-1 
p < 10-10 
#compared with intermediate chronotype (reference); $compared with 7-9 hrs sleep duration (reference). 
Adjusting for age, sex, socioeconomic status, education, BMI, hypertension, antihypertensive medication, 
cardiovascular disease, depressive symptoms, psychotropic medication and remaining sleep variables [sleep 
medication, chronotype, sleep duration, insomnia symptoms]. 
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Supplementary Table 1: Unadjusted and multivariate-adjusted relationships between insomnia 
status and cognitive performance. β values indicate unadjusted (model 1) and adjusted (models 2,3,4) 
group differences between three possible insomnia groupings [U = experiencing insomnia symptoms 
“usually” vs. “never/rarely”; S = experiencing insomnia symptoms “sometimes” vs. “never/rarely”; O = 
original test, experiencing insomnia symptoms “usually” vs. “sometimes”+”never/rarely”]. 
 
 
Cognitive Domain Model 1# Model 2## Model 3### Model 4#### 
     
Reasoning 
U: β = -1.9 x 10-1 *** 
S: β = -1.0 x 10-1 *** 
O: β = -1.2 x 10-1 *** 
U: β = 3.0 x 10-2 
S: β = 1.7 x 10-2 
O: β = 1.9 x 10-2 
U: β = 8.7 x 10-2 *** 
S: β = 4.1 x 10-2 * 
O: β = 5.9 x 10-2 *** 
U: β = 1.2 x 10-1 *** 
S: β = 4.4 x 10-2 * 
O: β = 9.5 x 10-2 *** 
      
Reaction Time 
U: β = 2.7 x 10-2 *** 
S: β = 2.0 x 10-2 *** 
O: β = 1.4 x 10-2 *** 
U: β = 1.7 x 10-4 
S: β = 3.6 x 10-3 *** 
O: β = -2.2 x 10-3 ** 
U: β = -4.9 x 10-3 *** 
S: β = 1.5 x 10-3  
O: β = -5.9 x 10-3 *** 
 
U: β = -5.7 x 10-3 *** 
S: β = 1.4 x 10-3  
O: β = -6.7 x 10-3 *** 
     
Numeric memory 
U: β = -1.7 x 10-1 *** 
S: β = -1.1 x 10-1 *** 
O: β = -1.0 x 10-1 *** 
U: β = -3.9 x 10-2 
S: β = -3.2 x 10-2 
O: β = -1.8 x 10-2 
U: β = -1.0 x 10-2 
S: β = -2.2 x 10-2 
O: β = 4.9 x 10-3 
U: β = 8.3 x 10-4 
S: β = -2.2 x 10-2 
O: β = 1.6 x 10-2 
      
Visual Memory 
U: β = 2.8 x 10-2 *** 
S: β = 2.0 x 10-2 *** 
O: β = 1.4 x 10-2 *** 
U: β = -9.0 x 10-3 * 
S: β = 2.2 x 10-5  
O: β = -9.0 x 10-3 ** 
U: β = -1.5 x 10-2 *** 
S: β = -3.0 x 10-3 
O: β = -1.3 x 10-2 *** 
U: β = -1.7 x 10-2 *** 
S: β = -3.1 x 10-3 
O: β = -1.4 x 10-2 *** 
     
Prospective Memory  
U: β = -9.2 x 10-2 *** 
S: β = -9.7 x 10-2 *** 
O: β = -2.7 x 10-2 
U: β = 5.8 x 10-2 * 
S: β = -5.2 x 10-3 
O: β = 6.1 x 10-2 *** 
U: β = 1.2 x 10-1 *** 
S: β = 2.2 x 10-2  
O: β = 1.1 x 10-1 *** 
U: β = 1.7 x 10-1*** 
S: β = 2.7 x 10-2 
O: β = 1.5 x 10-1 *** 
 
#unadjusted analyses; ##adjusting for age, gender, socioeconomic status and education 
###adjusting for age, gender, socioeconomic status, education, BMI, hypertension, 
antihypertensive medication, cardiovascular disease, depressive symptoms, psychotropic 
medication, sleep medication, chronotype; ####adjusting for Model 3 variables plus sleep 
duration. * p < 0.01; ** p < 0.001; *** p < 0.0001 
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Supplementary Table 2 (complete case analysis): Unadjusted and multivariate-
adjusted relationships between insomnia status and cognitive performance. β values 
indicate unadjusted (model 1) and adjusted (models 2, 3 and 4) group differences 
between those with and those without frequent insomnia symptoms. 
 
Cognitive Domain  Model 1# Model 2## Model 3### Model 4#### 
     
Reasoning β = -4.9 x 10-2 ** β = 2.6 x 10-2 β = 6.1 x 10-2 *** β = 9.5 x 10-2 *** 
  (n = 115,668) (n = 115,668) (n = 115,668) (n = 115,668) 
Reaction Time β = 1.1 x 10-2 *** β = -3.0 x 10-3 *** β = -5.9 x 10-3 *** β = -6.7 x 10-3 *** 
 (n = 332,303) (n = 332,303) (n = 332,303) (n = 332,303) 
Numeric memory β = -7.9 x 10-2 *** β = -1.7 x 10-2 β = 5.7 x 10-3 β = 1.6 x 10-2 
  (n = 34,753) (n = 34,753) (n = 34,753) (n = 34,753) 
Visual Memory β = 9.5 x 10-3 ** β = -9.0 x 10-3 ** β = -1.3 x 10-2 *** β = -1.4 x 10-2 *** 
 (n = 333,966) (n = 333,966) (n = 333,966) (n = 333,966) 
Prospective Memory β = 1.1 x 10-2 β = 6.7 x 10-2 *** β = 1.1 x 10-1 *** β = 1.5 x 10-1 *** 
 (n = 117,438) (n = 117,438) (n = 117,438) (n = 117,438) 
 
#unadjusted analyses; ##adjusting for age, sex, socioeconomic status and education; ###adjusting for age, sex, 
socioeconomic status, education, BMI, hypertension, cardiovascular disease, antihypertensive medication, 
depressive symptoms, psychotropic medication, sleep medication, chronotype; ####adjusting for Model 3 
variables plus sleep duration. * p < 0.01; ** p < 0.001; *** p < 0.0001
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
